Merck & Company Inc (MRK)vsTravere Therapeutics Inc (TVTX)
MRK
Merck & Company Inc
$128.33
+0.26%
HEALTHCARE · Cap: $316.14B
TVTX
Travere Therapeutics Inc
$62.76
+12.03%
HEALTHCARE · Cap: $5.20B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 12166% more annual revenue ($65.77B vs $536.20M). MRK leads profitability with a 13.6% profit margin vs -4.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
TVTX
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-58.0%
Fair Value
$81.23
Current Price
$128.33
$47.10 premium
Margin of Safety
+4.1%
Fair Value
$58.29
Current Price
$62.76
$4.47 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 55.6% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Trading at 58.7x book value
ROE of -69.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TVTX
The strongest argument for TVTX centers on Revenue Growth. Revenue growth of 55.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : TVTX
The primary concerns for TVTX are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 3.32 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while TVTX is a hypergrowth play — different risk/reward profiles.
TVTX carries more volatility with a beta of 1.11 — expect wider price swings.
TVTX is growing revenue faster at 55.6% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Travere Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?